Investment Gems

I don’t have a thesis about genomics. I have a dataset and this week it started pointing at the same place.

The motto here is distrust the story, and let the data tell you where it’s already moving. So I’m not going to open with a narrative about CRISPR curing disease or the “genomic revolution.” Those stories have been around for a decade and mostly lost people money. Instead, let me just report what the cross-section did.

For the last two weeks the headline has been a rotation out of mega-cap tech, the ten generals that led the entire bull market are rolling over, while breadth broadens underneath them. The money didn’t leave the market. It split into baskets. And this week, one of those baskets resolved into focus: genomics.

First, the macro, because the basket is downstream of it

You can’t read a sector breakout without the regime it’s breaking out into. Here’s the standing backdrop, straight from the panel:

• Yields are falling. Long bonds are bid (TLT +2.7% on the month). The rate cut the market spent a year arguing about is being priced.
• Commodities are collapsing. Gold −11%, oil −23%, silver −24%, uranium −12%, all over the past month. That is not a growth-scare tape; paired with falling yields it’s something cleaner.
• The dollar is firm and volatility is crushed (the vol complex is down a third over three months).

Count the bets and they’re not four trades, they’re one: disinflation. Falling commodities, falling yields, firm dollar, dead vol are all the same factor wearing different clothes. And there is one asset class that is pure leverage to falling long-rates: long-duration growth, companies whose value sits far out in the future, discounted back at a rate that is now dropping. The most extreme version of that on the Nasdaq isn’t software. It’s genomics: pre-profit, cash-burning, terminal-value-in-2035 biology. When the discount rate falls, these names don’t move, they lift off.

So the question isn’t “why genomics.” It’s “given this regime, where else would the money go?” The data just confirmed the obvious.

What the cross-section actually shows

Of the names breaking to new highs this week, a coherent genomics basket stands out, and it’s broad, not a single flyer. Twenty-five names I’d tag genomics, with a median three-month return of +33% against a whole-pool median of +4%. Eighty-four percent of them are positive on the month. This isn’t two rockets dragging an average; it’s a wall.

It comes in three strands, and reading them separately is the whole point:

1. Sequencing and DNA tools — the picks and shovels. Twist Bioscience +107% over three months, Maravai +98%, Illumina +43%. The companies that sell into everyone’s genomics program, regardless of which therapy wins.
2. Genomic diagnostics and liquid biopsy — the breadth. Veracyte +79%, NeoGenomics +77%, Guardant +62%, CareDx +59%, Natera +33%. A long, liquid list tagging highs together. One diagnostics name at a high is noise. Five is a rotation.
3. Gene and cell editing — the high-beta tail. Beam +44%, Taysha +44%, Intellia +21%. The lottery tickets. Moving, but messier — some already showing distribution.

The one honest tell: it needs volume

Here’s the part most write-ups would skip, and it’s the most important thing on the page. Almost every name in this basket carries the same tag in my screen: “momentum — needs volume.” Price is making new highs; relative volume is only running 1.0–2.0x normal. Translated: this is an emerging cluster, not a climaxing one. Breadth and price agree, but the heavy institutional sponsorship that turns a breakout into a trend hasn’t fully shown up yet.

That cuts both ways. The optimistic read is you’re early, in before the volume, which is exactly where you want to be. The disciplined read is that a breakout without volume is a hypothesis, not a confirmation, and it can fade before the buyers arrive. Only two names in the basket are actually volume-confirmed so far (Maravai and Natera). So I’m holding this as a probability, not a call, and I’m tracking basket volume daily to see whether sponsorship confirms or the move quietly dies. A forecast you never grade is just an opinion.

Two that are right at the edge of a breakout

If I’m going to do deeper work on this basket — and I am — two names earn it first, because both sit within about 2% of a fresh 52-week high on building volume:

Twist Bioscience (TWST). The infrastructure leader: synthetic DNA and sequencing tools, the most liquid of the high-velocity genomics names at roughly $270M traded a day. Up 107% over three months and pressing new highs. If you believe the theme but don’t want to bet on which therapy wins, you buy the company that sells shovels to all of them. This is the one I’m pulling filings on first.

NeoGenomics (NEO). The diagnostics breadth leader — cancer genomic testing, sitting right on a 52-week high with clean structure and +77% over three months. A more defensible, revenue-generating way into the basket than the editing names, and the chart is textbook.

Behind them, Maravai and Natera are the two that already have the volume the rest of the basket is waiting for — worth watching as the confirmation tell for the whole group.

The read, as exposures

1. Genomics = the sharpened disinflation trade. If long-rates keep falling, this is where the leverage is. Long-duration growth in its purest form.
2. It’s early, which means unconfirmed. Breadth is real; volume isn’t there yet. Size it as a probability, not a conviction.
3. Watch the volume and the credit canary. Basket volume tells you if the move is real; high-yield credit (still not confirming the broader rotation) tells you if the whole risk-on regime holds. If either cracks, this basket is fragile.

Leadership left mega-cap tech. This week, some of it moved into a corner of the market that only makes sense when the discount rate is falling. The macro set the table; the cross-section just showed me who sat down. Next week I’ll grade whether the volume showed up — and whether I was early or just wrong.